ALLIANCE PHARMA PLC

AGM Information • May 25, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1643G

Alliance Pharma PLC

25 May 2017

For immediate release	25 May 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

AGM Statement

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, will hold its Annual General Meeting ("AGM") in London later this morning. At the meeting, the Company's Chairman, Andrew Smith, will make the following statement:

"The year is proceeding well for the Company as we continue to develop our pan-European business.

"Trading in the current financial year is good and in line with the Board's expectations. Our key international growth brands, Kelo-Cote™, for scar reduction, and MacuShield™, a nutritional supplement product for age-related macular degeneration (AMD), continue to deliver a strong performance.

"We continue to expect that the UK registration approval for Diclectin, for the treatment for nausea and vomiting of pregnancy, will be granted in Q3 2017, which will enable us to begin commercial sales around the end of 2017 with sales in European territories following approximately 12 months later.

"Cash flow in the business remains strong and we are on target to reduce our adjusted net debt/EBITDA ratio to around 2x by the end of the year.

"We look forward to the year ahead with much confidence."

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMOKQDQABKDQPB